Healthcare Royalty Partners

GENFIT is a late-stage biopharmaceutical company focused on discovering and developing innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases with significant unmet medical needs. The company's expertise lies in targeting specific nuclear receptors and utilizing rational drug design, guided by the scientific leadership of Professor Bart Staels.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. Its lead therapies include Umbralisib (PI3K delta and CK1 epsilon inhibitor) for NHL and CLL, Ublituximab (CD20-targeting antibody) for NHL, CLL, and MS, Cosibelimab (PD-L1 inhibitor), TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific antibody). The company has strategic alliances with several pharmaceutical companies and generates revenue primarily in the United States.

OPKO Health is a multinational biotechnology company focused on pharmaceuticals and diagnostics. The Diagnostics segment operates BioReference Laboratories, a clinical laboratory network that provides routine testing, genetic testing, and related services. The Pharmaceutical segment develops and markets medicines across multiple therapeutic areas, including Rayaldee for secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency, as well as development programs such as OPK88004 and OPK88003, hGH-CTP (developed with Pfizer), VARUBI for chemotherapy-induced nausea and vomiting, and a Factor VIIa product for hemophilia. The company also manufactures specialty active pharmaceutical ingredients and markets nutraceuticals, over-the-counter products, and generics. It maintains global platforms and operations in Ireland, Chile, Spain, and Mexico, and pursues discovery, development, and commercialization in cancer, cardiovascular, metabolic, and genetic diseases. Founded in 1991, OPKO Health is headquartered in Miami, Florida.

Zevra Therapeutics is a biopharmaceutical company focused on developing safer therapies for pain, ADHD, and other CNS diseases. It employs its proprietary Ligand Activated Therapy platform to create abuse-resistant opioid pain relievers.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting pain and pruritus by selectively activating kappa opioid receptors. Its lead product candidate, KORSUVA (CR845/difelikefalin) injection, is in Phase III trials for treating moderate-to-severe chronic kidney disease-associated pruritus in hemodialysis patients. Cara also has other product candidates in various stages of clinical development for different indications, including oral formulations and applications beyond pruritus.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

Clearside Biomedical is a biopharmaceutical company focused on developing treatments for serious eye diseases. It specializes in delivering drugs directly to specific compartments of the eye using its proprietary suprachoroidal injection platform, aiming to restore and preserve vision.

Ardelyx is a biopharmaceutical company developing first-in-class, minimally absorbed oral medicines to treat mineral metabolism and metabolic disorders. Based in Fremont, California, founded in 2007. It focuses on non-systemic therapies that act in the intestines to modulate transporters and receptors, aiming to limit systemic exposure. Its lead product Tenapanor targets irritable bowel syndrome with constipation and hyperphosphatemia in chronic kidney disease on dialysis; the program includes Phase 3 trials. The company is pursuing additional candidates such as RDX013 for hyperkalemia, and RDX002 and RDX009 in earlier stages. Ardelyx aims to address cardiorenal and metabolic conditions using a non-systemic platform.

Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for treating rare genetic disorders that cause life-threatening metabolic issues. Its lead product candidate, setmelanotide, is a potent melanocortin-4 receptor agonist designed for precision medicine to treat hyperphagia and severe obesity resulting from rare MC4R pathway diseases.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development and commercialization of innovative therapeutics for thrombosis, hematologic disorders, and inflammation. Founded in 2003, Portola's lead product, Andexxa, serves as an antidote for patients treated with rivaroxaban and apixaban. The company's portfolio also includes Bevyxxa, an oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical illnesses. Additionally, Portola is developing investigational therapies such as cerdulatinib, a dual inhibitor targeting spleen tyrosine kinase and Janus kinases for hematologic cancers, and various Syk inhibitors for chronic inflammatory diseases. Portola collaborates with several major pharmaceutical companies to enhance its research and development efforts. As of July 2020, Portola operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Coherus Biosciences is a biopharmaceutical company focused on developing, manufacturing, and commercializing biologic therapeutics for oncology and inflammatory diseases. Its pipeline includes biosimilars for immunology, ophthalmology, and oncology.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

Invuity is a medical technology company that develops visualization products for minimally invasive and open surgeries. Using photonics technology, it directs and shapes light to provide broad, uniform illumination and direct visualization inside dark surgical cavities, enabling enhanced precision, efficiency, and safety. The product line includes illuminated retractors and handheld and intracavity illumination systems used in breast, orthopedic, spine, neurosurgery, endocrine, gynecologic, colorectal, and general procedures. Examples include Eikon LT and Eiberg illuminated retractors, PhotonBlade and PhotonSaber handheld illuminators, Breiten retractors, Photonguide XT intracavity illuminator, and PhotonVue visualization with indocyanine green imaging. Devices come in single-use and reusable formats and are sold directly to hospitals, surgeons, and to third-party manufacturers. Founded in 2004 and based in San Francisco, Invuity originated as Spotlight Surgical.

Helomics Corporation is a personalized healthcare company that develops diagnostic and tumor profiling solutions to guide cancer treatment decisions. Its Precision Cellular Analytical Platform analyzes cell cycle and proliferation data over a multiweek timeframe to support physicians in selecting effective therapies. The company offers products including ChemoFx for gynecologic cancers, BioSpeciFx biomarker tests to evaluate tumor biology and potential drug response or prognosis, GeneFx Colon for stage II colon cancer, and GeneFx Lung for early stage non-small cell lung cancer. It also provides tumor profiling services such as bioinformatics, contract research and development, and biorepository and banking. Helomics collaborates with industry partners to advance personalized oncology insights. The company was founded in 1995 and is based in Pittsburgh, Pennsylvania.

Cardiorentis AG is a biopharmaceutical company based in Zug, Switzerland, focused on developing innovative drug therapies for acute heart failure and related cardiovascular diseases. Founded in 2010, the company is dedicated to advancing novel treatment options, particularly through its key product, ularitide, which is designed for intravenous infusion in patients suffering from acute heart failure. In addition to its primary focus on ularitide, Cardiorentis conducts comprehensive studies, including safety and efficacy trials for patients with symptomatic and decompensated chronic heart failure. The company's approach combines expertise in protein biology with the development of small molecule compounds and peptides, aimed at addressing significant unmet medical needs in cardiology. Through collaborations with academic researchers, universities, and healthcare professionals, Cardiorentis is committed to driving impactful research that enhances patient care in a rapidly evolving medical landscape.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at improving near vision. Founded in 2001, the company develops and markets innovative solutions for presbyopia, including the KAMRA inlay, which helps patients restore their near vision without compromising distance vision. Additionally, AcuFocus offers the IC-8 IOL, a small aperture lens designed for cataract patients, providing a broad range of vision from near to far distances. The company also produces the AcuTarget HD, a diagnostic and surgical planning instrument that assists in the optimal treatment selection for various eye conditions such as LASIK, cataracts, and dry eye. AcuFocus distributes its products through partners across the Americas, Asia-Pacific, Europe, and the Middle East, serving both physicians and patients in the vision care market.

Raptor Pharmaceuticals is a biotechnology company focused on developing treatments for various brain disorders, genetic diseases, and cancer. Its pipeline includes products in clinical trials for conditions such as cystinosis, non-alcoholic steatohepatitis, Huntington's disease, migraine, acute pain, chronic pain, hepatocellular carcinoma, hepatitis C, breast cancer, and neurodegenerative diseases.

Invuity is a medical technology company that develops visualization products for minimally invasive and open surgeries. Using photonics technology, it directs and shapes light to provide broad, uniform illumination and direct visualization inside dark surgical cavities, enabling enhanced precision, efficiency, and safety. The product line includes illuminated retractors and handheld and intracavity illumination systems used in breast, orthopedic, spine, neurosurgery, endocrine, gynecologic, colorectal, and general procedures. Examples include Eikon LT and Eiberg illuminated retractors, PhotonBlade and PhotonSaber handheld illuminators, Breiten retractors, Photonguide XT intracavity illuminator, and PhotonVue visualization with indocyanine green imaging. Devices come in single-use and reusable formats and are sold directly to hospitals, surgeons, and to third-party manufacturers. Founded in 2004 and based in San Francisco, Invuity originated as Spotlight Surgical.

Nuron Biotech Inc. develops specialty biologics and vaccines. Its product pipeline comprises central nervous system products, such as NU100, a recombinant human interferon beta-1b for the treatment of relapsing remitting multiple sclerosis; wound healing products, including NU200, a recombinant human epidermal growth factor product for healing diabetic foot ulcers and burns; and HibTITER, a conjugate vaccine. The company was founded in 2010 and is based in Exton, Pennsylvania.

Suneva Medical develops, manufactures, and commercializes aesthetic products for dermatology and cosmetic surgery markets. Its flagship product, Bellafill, is a dermal filler used for correcting nasolabial folds and facial acne scars, with proven long-term safety and efficacy.

Suneva Medical develops, manufactures, and commercializes aesthetic products for dermatology and cosmetic surgery markets. Its flagship product, Bellafill, is a dermal filler used for correcting nasolabial folds and facial acne scars, with proven long-term safety and efficacy.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

Nuron Biotech Inc. develops specialty biologics and vaccines. Its product pipeline comprises central nervous system products, such as NU100, a recombinant human interferon beta-1b for the treatment of relapsing remitting multiple sclerosis; wound healing products, including NU200, a recombinant human epidermal growth factor product for healing diabetic foot ulcers and burns; and HibTITER, a conjugate vaccine. The company was founded in 2010 and is based in Exton, Pennsylvania.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at improving near vision. Founded in 2001, the company develops and markets innovative solutions for presbyopia, including the KAMRA inlay, which helps patients restore their near vision without compromising distance vision. Additionally, AcuFocus offers the IC-8 IOL, a small aperture lens designed for cataract patients, providing a broad range of vision from near to far distances. The company also produces the AcuTarget HD, a diagnostic and surgical planning instrument that assists in the optimal treatment selection for various eye conditions such as LASIK, cataracts, and dry eye. AcuFocus distributes its products through partners across the Americas, Asia-Pacific, Europe, and the Middle East, serving both physicians and patients in the vision care market.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.